期刊
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
卷 78, 期 -, 页码 -出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2022.129021
关键词
Muscarinic acetylcholine receptor 5; mAChR; M5; Antagonist
资金
- William K. Warren Family and Foundation
- Vanderbilt Institute of Chemical Biology
- Vanderbilt Ingram Cancer Center [P30 CA68485]
- Ancora Innovation, LLC
This Letter describes the ongoing effort to improve the clearance of selective M5 antagonists, reporting the replacement of the previously disclosed piperidine amide with a pyrrolidine amide core. The compounds in this series showed good potency, subtype selectivity, and moderate to low clearance profiles. Interestingly, the SAR for this series diverged from previous efforts.
This Letter describes our ongoing effort to improve the clearance of selective M5 antagonists. Herein, we report the replacement of the previously disclosed piperidine amide (4, disclosed in Part 1) with a pyrrolidine amide core. Several compounds within this series provided good potency, subtype selectivity, and low to moderate clearance profiles. Interestingly, the left-hand side SAR for this series diverged from our earlier efforts.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据